Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Mish's Global Economic Trend Analysis -- Ignore unavailable to you. Want to Upgrade?

To: Elroy Jetson who wrote (40341)	11/1/2005 8:20:46 AM
From: Casaubon	Read Replies (1) \| Respond to of 116555

I watched a seminar from Judah Folkman on anti-angionesis that looked like THE CURE for cancer (remember Entremed?). While the concept was unique and very important for a whole line of important medical reasoning, his drugs failed to work. It was THE CURE, for MICE. news.harvard.edu These things happen fairly often in research. Sometimes very good ideas have marginal success in medicine. Often, they just outright fail. Mice are easy to cure (especially under optimized conditions of study), while humans are not. And why should I care? Because you used a very simplistic mouse study to try and validate the use of Tamiflu, for an unvalidated therapeutic use. Whereas, the clinical body of evidence for that drug demonstrate marginal results at best, for non-lethal strains of influenza!